Overview

Reparixin in COVID-19 Pneumonia - Efficacy and Safety

Status:
Terminated
Trial end date:
2021-02-02
Target enrollment:
Participant gender:
Summary
- Phase 2 Study Objectives: efficacy and safety of of Reparixin treatment as compared to the control arm in adult patients with severe COVID-19 pneumonia - Phase 3 Study Objectives: efficacy and safety of Reparixin treatment as compared to the control arm in adult patients with moderate or severe COVID-19 pneumonia
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Dompé Farmaceutici S.p.A